Quick Answer
AbbVie Inc. reported Cash and Equivalents of $5.23 billion for fiscal year 2025.
AbbVie Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.23B | -5.3% |
| 2024 | $5.52B | -56.9% |
| 2023 | $12.81B | +39.3% |
| 2022 | $9.20B | -5.6% |
| 2021 | $9.75B | +15.4% |
| 2020 | $8.45B | -78.8% |
| 2019 | $39.92B | +447.7% |
| 2018 | $7.29B | -21.6% |
| 2017 | $9.30B | +82.4% |
| 2016 | $5.10B | -39.3% |
| 2015 | $8.40B | +0.6% |
| 2014 | $8.35B | -13.0% |
| 2013 | $9.60B | +62.6% |
| 2012 | $5.90B | +21755.6% |
| 2011 | $27.00M | +170.0% |
| 2010 | $10.00M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.63B | -22.4% | -13.0% |
| June 30, 2025 | $6.47B | -50.7% | +25.0% |
| March 31, 2025 | $5.17B | -71.4% | -6.3% |
| December 31, 2024 | $5.52B | -56.9% | -23.9% |
| September 30, 2024 | $7.26B | -45.4% | -44.7% |
| June 30, 2024 | $13.13B | +49.9% | -27.3% |
| March 31, 2024 | $18.07B | +169.2% | +41.0% |
| December 31, 2023 | $12.81B | +39.3% | -3.6% |
- AbbVie Inc. showed a decrease of -5.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, AbbVie Inc.’s cash and equivalents has grown by 52190.0% (from $10.00 million to $5.23 billion).
- The most recent figure is from AbbVie Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: